Literature DB >> 30887209

Can peritumoral radiomics increase the efficiency of the prediction for lymph node metastasis in clinical stage T1 lung adenocarcinoma on CT?

Xiang Wang1, Xingyu Zhao2,3, Qiong Li1, Wei Xia3, Zhaohui Peng1, Rui Zhang3, Qingchu Li1, Junming Jian2,3, Wei Wang1, Yuguo Tang3, Shiyuan Liu4, Xin Gao5.   

Abstract

OBJECTIVES: To evaluate the efficiency of radiomics model on CT images of intratumoral and peritumoral lung parenchyma for preoperative prediction of lymph node (LN) metastasis in clinical stage T1 peripheral lung adenocarcinoma patients.
METHODS: Three hundred sixty-six peripheral lung adenocarcinoma patients with clinical stage T1 were evaluated using five CT scanners. For each patient, two volumes of interest (VOIs) on CT were defined as the gross tumor volume (GTV) and the peritumoral volume (PTV, 1.5 cm around the tumor). One thousand nine hundred forty-six radiomic features were obtained from each VOI, and then refined for reproducibility and redundancy. The refined features were investigated for usefulness in building radiomic signatures by mRMR feature ranking method and LASSO classifier. Multivariable logistic regression analysis was used to develop a radiomic nomogram incorporating the radiomic signature and clinical parameters. The prediction performance was evaluated on the validation cohort.
RESULTS: The radiomic signatures using the features of GTV and PTV showed a good ability in predicting LN metastasis with an AUC of 0.829 (95% CI, 0.745-0.913) and 0.825 (95% CI, 0.733-0.918), respectively. By incorporating the features of GTV and PTV, the AUC of radiomic signature increased to 0.843 (95% CI, 0.770-0.916). The AUC of radiomic nomogram was 0.869 (95% CI, 0.800-0.938).
CONCLUSIONS: Radiomic signatures of GTV and PTV both had a good prediction ability in the prediction of LN metastasis, and there is no significant difference of AUC between the two groups. The proposed nomogram can be conveniently used to facilitate the preoperative prediction of LN metastasis in T1 peripheral lung adenocarcinomas. KEY POINTS: • Radiomics from peritumoral lung parenchyma increase the efficiency of the prediction for lymph node metastasis in clinical stage T1 lung adenocarcinoma on CT. • A radiomic nomogram was developed and validated to predict LN metastasis. • Different scan parameters on CT showed that radiomics signature had good predictive performance.

Entities:  

Keywords:  Adenocarcinoma; Lung; Lymph node; Metastasis; Radiomics

Mesh:

Year:  2019        PMID: 30887209     DOI: 10.1007/s00330-019-06084-0

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  30 in total

1.  A Bounding Box-Based Radiomics Model for Detecting Occult Peritoneal Metastasis in Advanced Gastric Cancer: A Multicenter Study.

Authors:  Dan Liu; Weihan Zhang; Fubi Hu; Pengxin Yu; Xiao Zhang; Hongkun Yin; Lanqing Yang; Xin Fang; Bin Song; Bing Wu; Jiankun Hu; Zixing Huang
Journal:  Front Oncol       Date:  2021-12-03       Impact factor: 6.244

2.  Development and validation of a deep learning signature for predicting lymph node metastasis in lung adenocarcinoma: comparison with radiomics signature and clinical-semantic model.

Authors:  Xiaoling Ma; Liming Xia; Jun Chen; Weijia Wan; Wen Zhou
Journal:  Eur Radiol       Date:  2022-09-28       Impact factor: 7.034

3.  Peritumoral radiomics features on preoperative thin-slice CT images can predict the spread through air spaces of lung adenocarcinoma.

Authors:  Keiichi Takehana; Ryo Sakamoto; Koji Fujimoto; Yukinori Matsuo; Naoki Nakajima; Akihiko Yoshizawa; Toshi Menju; Mitsuhiro Nakamura; Ryo Yamada; Takashi Mizowaki; Yuji Nakamoto
Journal:  Sci Rep       Date:  2022-06-20       Impact factor: 4.996

4.  Prediction of Two-Year Recurrence-Free Survival in Operable NSCLC Patients Using Radiomic Features from Intra- and Size-Variant Peri-Tumoral Regions on Chest CT Images.

Authors:  Soomin Lee; Julip Jung; Helen Hong; Bong-Seog Kim
Journal:  Diagnostics (Basel)       Date:  2022-05-25

5.  Differentiation of Cerebral Dissecting Aneurysm from Hemorrhagic Saccular Aneurysm by Machine-Learning Based on Vessel Wall MRI: A Multicenter Study.

Authors:  Xin Cao; Yanwei Zeng; Junying Wang; Yunxi Cao; Yifan Wu; Wei Xia
Journal:  J Clin Med       Date:  2022-06-23       Impact factor: 4.964

6.  18F-FDG PET-based radiomics model for predicting occult lymph node metastasis in clinical N0 solid lung adenocarcinoma.

Authors:  Lili Wang; Tiancheng Li; Junjie Hong; Mingyue Zhang; Mingli Ouyang; Xiangwu Zheng; Kun Tang
Journal:  Quant Imaging Med Surg       Date:  2021-01

7.  Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First Transarterial Chemoembolization in Hepatocellular Carcinoma.

Authors:  Mingyu Chen; Jiasheng Cao; Jiahao Hu; Win Topatana; Shijie Li; Sarun Juengpanich; Jian Lin; Chenhao Tong; Jiliang Shen; Bin Zhang; Jennifer Wu; Christine Pocha; Masatoshi Kudo; Amedeo Amedei; Franco Trevisani; Pil Soo Sung; Victor M Zaydfudim; Tatsuo Kanda; Xiujun Cai
Journal:  Liver Cancer       Date:  2021-01-07       Impact factor: 11.740

8.  Development and Validation of a Combined Model for Preoperative Prediction of Lymph Node Metastasis in Peripheral Lung Adenocarcinoma.

Authors:  Qi Li; Xiao-Qun He; Xiao Fan; Chao-Nan Zhu; Jun-Wei Lv; Tian-You Luo
Journal:  Front Oncol       Date:  2021-05-24       Impact factor: 6.244

9.  A Comprehensive Nomogram Combining CT Imaging with Clinical Features for Prediction of Lymph Node Metastasis in Stage I-IIIB Non-small Cell Lung Cancer.

Authors:  Xingxing Zheng; Jingjing Shao; Linli Zhou; Li Wang; Yaqiong Ge; Gaoren Wang; Feng Feng
Journal:  Ther Innov Regul Sci       Date:  2021-10-26       Impact factor: 1.778

10.  CT-based radiomics signatures can predict the tumor response of non-small cell lung cancer patients treated with first-line chemotherapy and targeted therapy.

Authors:  Fengchang Yang; Jiayi Zhang; Liu Zhou; Wei Xia; Rui Zhang; Haifeng Wei; Jinxue Feng; Xingyu Zhao; Junming Jian; Xin Gao; Shuanghu Yuan
Journal:  Eur Radiol       Date:  2021-09-26       Impact factor: 7.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.